Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
1.12T
Market cap1.12T
Price-Earnings ratio
42.54
Price-Earnings ratio42.54
Dividend yield
0.55%
Dividend yield0.55%
Average volume
2.75M
Average volume2.75M
High today
$1,184.99
High today$1,184.99
Low today
$1,172.00
Low today$1,172.00
Open price
$1,181.63
Open price$1,181.63
Volume
11.19K
Volume11.19K
52 Week high
$1,249.45
52 Week high$1,249.45
52 Week low
$623.78
52 Week low$623.78

Stock Snapshot

As of today, Eli Lilly(LLY) shares are valued at $1,172.00. The company's market cap stands at 1.12T, with a P/E ratio of 42.54 and a dividend yield of 0.55%.

During the trading session on 2026-07-14, Eli Lilly(LLY) shares reached a daily high of $1,184.99 and a low of $1,172.00. At a current price of $1,172.00, the stock is 0.0% higher than the low and still -1.1% under the high.

Trading volume for Eli Lilly(LLY) stock has reached 11.19K, versus its average volume of 2.75M.

The stock's 52-week range extends from a low of $623.78 to a high of $1,249.45.

The stock's 52-week range extends from a low of $623.78 to a high of $1,249.45.

LLY News

TipRanks 53m
Eli Lilly price target raised to $1,385 from $1,300 at Bernstein

Bernstein raised the firm’s price target on Eli Lilly (LLY) to $1,385 from $1,300 and keeps an Outperform rating on the shares. Eli Lilly shares have performed...

Investing.com 2h
Bernstein raises Eli Lilly stock price target on beat potential - Investing.com

...

Bernstein raises Eli Lilly stock price target on beat potential - Investing.com
TipRanks 19h
Eli Lilly Stock Gets a Price Target Boost Heading into Earnings

Wall Street brokerage Guggenheim has raised its price target on Eli Lilly’s (LLY) stock heading into the company’s second-quarter earnings print, saying weight-...

Analyst ratings

84%

of 31 ratings
Buy
83.9%
Hold
9.7%
Sell
6.5%

More LLY News

24/7 Wall St. 19h
Prediction: 1 New Reason Eli Lilly Stock Could Still Be Headed Higher

Prediction: 1 New Reason Eli Lilly Stock Could Still Be Headed Higher By Vandita Jadeja Published Jul 13, 2:00PM EDT Quick Read LLY earns a BUY with a $1,336...

Prediction: 1 New Reason Eli Lilly Stock Could Still Be Headed Higher
Benzinga 1d
Eli Lilly Stock in Focus as Company Presents New Kisunla Data at AAIC Following Wave of Analyst Upgrades

Eli Lilly and Company (NYSE:LLY) shares are in the spotlight Monday as the company presents new data at the Alzheimer’s Association International Conference in...

Eli Lilly Stock in Focus as Company Presents New Kisunla Data at AAIC Following Wave of Analyst Upgrades
The Motley Fool 1d
Here's How Much Eli Lilly's Weight-Loss Drugs Are Worth to Investors

Eli Lilly (LLY 2.30%) commands a market capitalization of about $1.06 trillion, and that valuation was built largely on two drugs: Mounjaro and Zepbound. Invest...

Here's How Much Eli Lilly's Weight-Loss Drugs Are Worth to Investors
Nasdaq 3d
Should You Buy Eli Lilly Stock? Here's My Honest Take.

Key Points Lilly's business is booming. However, there is a bear case against the pharma stock. One smart strategy could be to gradually build a position in...

Should You Buy Eli Lilly Stock? Here's My Honest Take.
Simply Wall St 4d
Eli Lilly Wins Canada Backing For Ebglyss As Oncology Progress Builds

Eli Lilly's eczema drug Ebglyss received a positive recommendation from Canada's Drug Agency, supporting future public reimbursement. The company agreed a new...

Eli Lilly Wins Canada Backing For Ebglyss As Oncology Progress Builds
TipRanks 4d
Eli Lilly’s New Neuropathic Pain Trial Reaches Phase 2 Completion: What Investors Should Watch

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. TipRanks has entered a new arena in the investing world, powering the index of...

Nasdaq 5d
Record Numbers of Americans Are on GLP-1 Drugs. That's Great News for This Stock.

Key Points More Americans than ever are using GLP-1 drugs. Eli Lilly recently rolled out an oral weight loss drug. 10 stocks we like better than Eli Lilly ›...

Record Numbers of Americans Are on GLP-1 Drugs. That's Great News for This Stock.

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.